185 related articles for article (PubMed ID: 35059859)
1. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.
Kayabasi C; Caner A; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Asik A; Mutlu Z; Caliskan Kurt C; Goker Bagca B; Biray Avci C; Sahin F; Saydam G; Gunduz C
Med Oncol; 2022 Jan; 39(3):29. PubMed ID: 35059859
[TBL] [Abstract][Full Text] [Related]
2. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
[TBL] [Abstract][Full Text] [Related]
4. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
[TBL] [Abstract][Full Text] [Related]
6. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
Goker B; Caliskan C; Onur Caglar H; Kayabasi C; Balci T; Erbaykent Tepedelen B; Aygunes D; Yilmaz Susluer S; Mutlu Z; Selvi Gunel N; Korkmaz M; Saydam G; Gunduz C; Biray Avci C
J BUON; 2014; 19(4):992-8. PubMed ID: 25536607
[TBL] [Abstract][Full Text] [Related]
9. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells.
Kato Y; Kunimasa K; Sugimoto Y; Tomida A
Biochem Biophys Res Commun; 2018 Oct; 504(4):721-726. PubMed ID: 30217442
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
12. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.
Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB
Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085
[TBL] [Abstract][Full Text] [Related]
13. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.
Miller GD; Woessner DW; Sirch MJ; Lim CS
Mol Pharm; 2013 Sep; 10(9):3475-83. PubMed ID: 23915432
[TBL] [Abstract][Full Text] [Related]
14. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
[No Abstract] [Full Text] [Related]
16. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.
Traer E; Javidi-Sharifi N; Agarwal A; Dunlap J; English I; Martinez J; Tyner JW; Wong M; Druker BJ
Blood; 2014 Mar; 123(10):1516-24. PubMed ID: 24408322
[TBL] [Abstract][Full Text] [Related]
17. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD; Holyoake TL
Stem Cells; 2014 Sep; 32(9):2324-37. PubMed ID: 24806995
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
[TBL] [Abstract][Full Text] [Related]
19.
Kayabasi C; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Mutlu Z; Goker Bagca B; Caliskan Kurt C; Saydam G; Durmuskahya C; Kayalar H; Ozbilgin A; Biray Avci C; Gunduz C
Nutr Cancer; 2022; 74(10):3679-3691. PubMed ID: 35608652
[No Abstract] [Full Text] [Related]
20. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]